Prana's PBT2 Reverses Memory Loss in Normal Aging - Seite 2

"In my view, these data help explain why other Alzheimer's therapies that solely target Abeta or tau pathology may, at best, be only partially effective. PBT2, by addressing metal induced oligomer formation, restoring metal balance in affected brain regions, and by promoting new neuronal cell growth, elicits a distinct set of disease modifying effects. Thus PBT2 may not only ameliorate Alzheimers pathology, but perhaps other detrimental aspects of aging on the brain," concluded Dr Tanzi. 

Synopsis of the Aging Cell publication

Typically mice live for 24 to 30 months, developing progressive cognitive impairment from 16 to 18 months. Age related cognitive decline is associated with measurable structural and biochemical changes in the brain, which were significantly improved by PBT2. In the study 22 month old mice were treated with PBT2 for a total of 12 days.

• PBT2 restored learning and memory. The old mice treated with PBT2 performed learning and memory tasks to the same level exhibited by young mice and significantly better than untreated old mice (p < .01 or better). 
• PBT2 Increases markers of neurogenesis and neuron number:
  a) Increased number of mature neurons by up to 27% in the hippocampus 
  b) Increased markers of cell proliferation by 67% and markers of numbers of immature neurons by 130% in the hippocampus.
  c) Neuronal proliferation markers were elevated around the lateral ventricles by 214% (atrophy of peri-ventricular tissue is a feature of Huntington's disease) 
• PBT2 increases numbers of synapses in the hippocampus:
  a) Synaptophysin levels increased by 38%
  b) Dendritic spine density increased by 15%
• PBT2 increases glutamate receptor levels in the hippocampus:
  a) NMDA R2b levels increased by 88%
  b) AMPA levels increased by 97%
• PBT2 increases Protein Phosphotase 2a (PP2a) in the hippocampus:
  a) PP2a increased by 22%
  b) Phosphorylated Tau levels decreased by 81%

* Adlard et al, A Novel Approach To Rapidly Prevent Age-Related Cognitive Decline
http://onlinelibrary.wiley.com/doi/10.1111/acel.12178/pdf

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.